Related Experiment Video
Updated: Sep 14, 2025
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Optimizing primary tumor resection decisions for non-small cell lung cancer patients with brain metastases: analysis
Yuyu Lin1, Weishuai Wu2, Xiaoting Su1
1Shengli Clinical College of Fujian Medical University, Department of Thoracic Surgery, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China.
Background:
Brain metastases (BM) in non-small cell lung cancer (NSCLC) are associated with poor prognosis, and the role of primary tumor resection (PTR) remains controversial. This study aims to evaluate the role of PTR in NSCLC patients with BM and develop a predictive tool to identify optimal surgical candidates.
Methods:
We analyzed data from 608 patients who underwent PTR and 18,529 patients who did not, sourced from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (PSM), a statistical method to balance baseline characteristics between treatment groups, was performed to minimize selection bias. We utilized Kaplan-Meier (KM) survival analysis, Cox regression analysis, and PSM to assess the impact of PTR on the prognosis of BM patients. Logistic regression analysis was performed to identify and quantify the clinical factors that influence the benefits of PTR in BM patients, which informed the development of a predictive model. The model's predictive accuracy and clinical applicability were evaluated using the Concordance index (C-index), F1 score, receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA), with 42 patients from Fujian Provincial Hospital serving as the external validation cohort.
Results:
KM survival analysis revealed significant survival differences between the PTR and non-PTR groups, both before and after PSM, with median survival times of 15 and 7 months, respectively. PTR was identified as an independent clinical factor affecting the prognosis of BM patients. In the training set, the C-index for the model was 0.7857 [95% confidence interval (CI): 0.7387-0.8327]. In the validation set, the C-index was 0.7441 (95% CI: 0.6674-0.8208), and in the external validation set, it was 0.7759 (95% CI: 0.5855-0.9662). The F1 score of the predictive model was 0.7667. Analyses of the ROC curve, calibration curve, and DCA indicated that the model exhibits strong accuracy and clinical applicability.
Conclusions:
This study indicated that PTR can enhance the prognosis of NSCLC patients with BM and also establishes an effective screening tool for quantifying the likelihood of patient benefiting from PTR treatment.
